The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
A veteran in cell therapy and oncology commercialisation
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
He will be stationed at the company HQ in Bengaluru, India
Subscribe To Our Newsletter & Stay Updated
